Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2018

Cheleuitte-Nieves C, Gulvik CA, Humrighouse BW, Bell ME, Villarma A, Westblade LF, et al. Draft Reference Genome Sequence of 16-1433, Isolated from a Mouse. Genome Announc. 2018;6(7).

Conteduca V, Sigouros M, Sboner A, Pritchard CC, Beltran H. BRCA2-Associated Prostate Cancer in a Patient With Spinal and Bulbar Muscular Atrophy. JCO Precis Oncol. 2018;2.

Zhao Z, Sun Q, Sokoll LJ, Streiff M, Cheng Z, Grasmeder S, et al. Eltrombopag mobilizes iron in patients with aplastic anemia. Blood. 2018;131(21):2399-2402.

Reid EG, Looney D, Maldarelli F, Noy A, Henry D, Aboulafia D, et al. Safety and efficacy of an oncolytic viral strategy using bortezomib with ICE/R in relapsed/refractory HIV-positive lymphomas. Blood Adv. 2018;2(24):3618-3626.

Santo EE, Paik J. FOXO in Neural Cells and Diseases of the Nervous System. Curr Top Dev Biol. 2018;127:105-118.

Nakahara T, Petrov A, Tanimoto T, Chaudhry F, Narula N, Seshan SV, et al. Molecular Imaging of Apoptosis in Cancer Therapy-Related Cardiac Dysfunction Before LVEF Reduction. JACC Cardiovasc Imaging. 2018;11(8):1203-1205.

Avecilla ST, Goss C, Marionneaux SM, Wright DR, Leiva TD, Tonon J-, et al. Method comparison study of peripheral blood CD34+ count performed on an Abbott CELL-DYN Sapphire hematology analyzer versus flow cytometry reference procedure (modified ISHAGE). Adv Cell Gene Ther. 2018;1(2).

Rutherford SC, Stewart EN, Chen Z, Chadburn A, Wehrli NE, Van Besien K, et al. The eIF4E inhibitor ribavirin as a potential antilymphoma therapeutic: early clinical data^. Leuk Lymphoma. 2018;59(1):256-258.

Graff RE, Ahearn TU, Pettersson A, Ebot EM, Gerke T, Penney KL, et al. Height, Obesity, and the Risk of -Defined Prostate Cancer. Cancer Epidemiol Biomarkers Prev. 2018;27(2):193-200.

DeSimone RA, Leung WK, Schwartz J. Transfusion Medicine in a Multidisciplinary Approach to Morbidly Adherent Placenta: Preparing for and Preventing the Worst. Transfus Med Rev. 2018;32(4):244-248.